Cargando…

Reduction of MRI-targeted biopsies in men with low-risk prostate cancer on active surveillance by stratifying to PI-RADS and PSA-density, with different thresholds for significant disease

BACKGROUND: The fear of undergrading prostate cancer (PCa) in men on active surveillance (AS) have led to strict criteria for monitoring, which have resulted in good long-term cancer-specific survival, proving the safety of this approach. Reducing undergrading, MRI-targeted biopsies are increasingly...

Descripción completa

Detalles Bibliográficos
Autores principales: Schoots, Ivo G., Osses, Daniel F., Drost, Frank-Jan H., Verbeek, Jan F. M., Remmers, Sebastiaan, van Leenders, Geert J. L. H., Bangma, Chris H., Roobol, Monique J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5861278/
https://www.ncbi.nlm.nih.gov/pubmed/29594027
http://dx.doi.org/10.21037/tau.2017.12.29
_version_ 1783308063313231872
author Schoots, Ivo G.
Osses, Daniel F.
Drost, Frank-Jan H.
Verbeek, Jan F. M.
Remmers, Sebastiaan
van Leenders, Geert J. L. H.
Bangma, Chris H.
Roobol, Monique J.
author_facet Schoots, Ivo G.
Osses, Daniel F.
Drost, Frank-Jan H.
Verbeek, Jan F. M.
Remmers, Sebastiaan
van Leenders, Geert J. L. H.
Bangma, Chris H.
Roobol, Monique J.
author_sort Schoots, Ivo G.
collection PubMed
description BACKGROUND: The fear of undergrading prostate cancer (PCa) in men on active surveillance (AS) have led to strict criteria for monitoring, which have resulted in good long-term cancer-specific survival, proving the safety of this approach. Reducing undergrading, MRI-targeted biopsies are increasingly used in men with low-risk disease despite their undefined role yet. The objective of this study is to investigate the rate of upgrading using MRI-targeted biopsies in men with low-risk disease on AS, stratified on the basis of PI-RADS and PSA-density, with the aim to reduce potential unnecessary repeat biopsy procedures. METHODS: A total of 331 men were prospectively enrolled following the MRI-PRIAS protocol. MR imaging was according to Prostate Imaging Reporting and Data System (PI-RADSv2) guidelines. Suspicious MRI lesions (PI-RADS 3–5) were additionally targeted by MRI-TRUS fusion biopsies. Outcome measure was upgrading to Gleason score (GS) ≥3+4 with MRI-targeted biopsies, stratified for PI-RADS and PSA-density. RESULTS: In total, 25% (82/331) of men on AS showed upgrading from GS 3+3. Only 3% (11/331) was upgraded to GS ≥8. In 60% (198/331) a suspicious MRI lesion was identified, but in only 41% (82/198) of men upgrading was confirmed. PI-RADS 3, 4 and 5 categorized index lesions, showed upgrading in 30%, 34% and 66% of men, respectively. Stratification to PI-RADS 4–5, instead of PI-RADS 3–5, would have missed a small number of high volume Gleason 4 PCa in PI-RADS 3 category. However, further stratification into PI-RADS 3 lesions and PSA-density <0.15 ng/mL(2) could result in a safe targeted biopsy reduction of 36% in this category, without missing any upgrades. CONCLUSIONS: Stratification with the combination of PI-RADS and PSA-density may reduce unnecessary additional MRI biopsy testing. Overall, the high rate of detected upgrading in men on AS may result in an unintended tightening of continuing in AS. Since patients, included under current AS criteria showed extremely favorable outcome, there might be no need to further restrict continuing on AS with MRI and targeted biopsies.
format Online
Article
Text
id pubmed-5861278
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-58612782018-03-28 Reduction of MRI-targeted biopsies in men with low-risk prostate cancer on active surveillance by stratifying to PI-RADS and PSA-density, with different thresholds for significant disease Schoots, Ivo G. Osses, Daniel F. Drost, Frank-Jan H. Verbeek, Jan F. M. Remmers, Sebastiaan van Leenders, Geert J. L. H. Bangma, Chris H. Roobol, Monique J. Transl Androl Urol Original Article BACKGROUND: The fear of undergrading prostate cancer (PCa) in men on active surveillance (AS) have led to strict criteria for monitoring, which have resulted in good long-term cancer-specific survival, proving the safety of this approach. Reducing undergrading, MRI-targeted biopsies are increasingly used in men with low-risk disease despite their undefined role yet. The objective of this study is to investigate the rate of upgrading using MRI-targeted biopsies in men with low-risk disease on AS, stratified on the basis of PI-RADS and PSA-density, with the aim to reduce potential unnecessary repeat biopsy procedures. METHODS: A total of 331 men were prospectively enrolled following the MRI-PRIAS protocol. MR imaging was according to Prostate Imaging Reporting and Data System (PI-RADSv2) guidelines. Suspicious MRI lesions (PI-RADS 3–5) were additionally targeted by MRI-TRUS fusion biopsies. Outcome measure was upgrading to Gleason score (GS) ≥3+4 with MRI-targeted biopsies, stratified for PI-RADS and PSA-density. RESULTS: In total, 25% (82/331) of men on AS showed upgrading from GS 3+3. Only 3% (11/331) was upgraded to GS ≥8. In 60% (198/331) a suspicious MRI lesion was identified, but in only 41% (82/198) of men upgrading was confirmed. PI-RADS 3, 4 and 5 categorized index lesions, showed upgrading in 30%, 34% and 66% of men, respectively. Stratification to PI-RADS 4–5, instead of PI-RADS 3–5, would have missed a small number of high volume Gleason 4 PCa in PI-RADS 3 category. However, further stratification into PI-RADS 3 lesions and PSA-density <0.15 ng/mL(2) could result in a safe targeted biopsy reduction of 36% in this category, without missing any upgrades. CONCLUSIONS: Stratification with the combination of PI-RADS and PSA-density may reduce unnecessary additional MRI biopsy testing. Overall, the high rate of detected upgrading in men on AS may result in an unintended tightening of continuing in AS. Since patients, included under current AS criteria showed extremely favorable outcome, there might be no need to further restrict continuing on AS with MRI and targeted biopsies. AME Publishing Company 2018-02 /pmc/articles/PMC5861278/ /pubmed/29594027 http://dx.doi.org/10.21037/tau.2017.12.29 Text en 2018 Translational Andrology and Urology. All rights reserved.
spellingShingle Original Article
Schoots, Ivo G.
Osses, Daniel F.
Drost, Frank-Jan H.
Verbeek, Jan F. M.
Remmers, Sebastiaan
van Leenders, Geert J. L. H.
Bangma, Chris H.
Roobol, Monique J.
Reduction of MRI-targeted biopsies in men with low-risk prostate cancer on active surveillance by stratifying to PI-RADS and PSA-density, with different thresholds for significant disease
title Reduction of MRI-targeted biopsies in men with low-risk prostate cancer on active surveillance by stratifying to PI-RADS and PSA-density, with different thresholds for significant disease
title_full Reduction of MRI-targeted biopsies in men with low-risk prostate cancer on active surveillance by stratifying to PI-RADS and PSA-density, with different thresholds for significant disease
title_fullStr Reduction of MRI-targeted biopsies in men with low-risk prostate cancer on active surveillance by stratifying to PI-RADS and PSA-density, with different thresholds for significant disease
title_full_unstemmed Reduction of MRI-targeted biopsies in men with low-risk prostate cancer on active surveillance by stratifying to PI-RADS and PSA-density, with different thresholds for significant disease
title_short Reduction of MRI-targeted biopsies in men with low-risk prostate cancer on active surveillance by stratifying to PI-RADS and PSA-density, with different thresholds for significant disease
title_sort reduction of mri-targeted biopsies in men with low-risk prostate cancer on active surveillance by stratifying to pi-rads and psa-density, with different thresholds for significant disease
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5861278/
https://www.ncbi.nlm.nih.gov/pubmed/29594027
http://dx.doi.org/10.21037/tau.2017.12.29
work_keys_str_mv AT schootsivog reductionofmritargetedbiopsiesinmenwithlowriskprostatecanceronactivesurveillancebystratifyingtopiradsandpsadensitywithdifferentthresholdsforsignificantdisease
AT ossesdanielf reductionofmritargetedbiopsiesinmenwithlowriskprostatecanceronactivesurveillancebystratifyingtopiradsandpsadensitywithdifferentthresholdsforsignificantdisease
AT drostfrankjanh reductionofmritargetedbiopsiesinmenwithlowriskprostatecanceronactivesurveillancebystratifyingtopiradsandpsadensitywithdifferentthresholdsforsignificantdisease
AT verbeekjanfm reductionofmritargetedbiopsiesinmenwithlowriskprostatecanceronactivesurveillancebystratifyingtopiradsandpsadensitywithdifferentthresholdsforsignificantdisease
AT remmerssebastiaan reductionofmritargetedbiopsiesinmenwithlowriskprostatecanceronactivesurveillancebystratifyingtopiradsandpsadensitywithdifferentthresholdsforsignificantdisease
AT vanleendersgeertjlh reductionofmritargetedbiopsiesinmenwithlowriskprostatecanceronactivesurveillancebystratifyingtopiradsandpsadensitywithdifferentthresholdsforsignificantdisease
AT bangmachrish reductionofmritargetedbiopsiesinmenwithlowriskprostatecanceronactivesurveillancebystratifyingtopiradsandpsadensitywithdifferentthresholdsforsignificantdisease
AT roobolmoniquej reductionofmritargetedbiopsiesinmenwithlowriskprostatecanceronactivesurveillancebystratifyingtopiradsandpsadensitywithdifferentthresholdsforsignificantdisease